SRPT Overview
Upcoming Projects (SRPT)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (SRPT)
-
Analyzing Capricor's Mid-Cycle Review Update for Deramiocel in Duchenne Muscular Dystrophy Cardiomyopathy
Tickers: CAPR, SRPT
Executed On: Jul 18, 2025 at 02:00 PM EDT -
Discussing the second death of a patient who was treated with Elevidys the effect on future prescribing and uptake
Ticker: SRPT
Executed On: Jul 03, 2025 at 09:00 AM EDT -
A third look: Discussing the recent death of a patient who was treated with Elevidys the effect on future prescribing and uptake
Ticker: SRPT
Executed On: Apr 22, 2025 at 09:30 AM EDT -
A second look: Discussing the recent death of a patient who was treated with Elevidys the effect on future prescribing and uptake
Ticker: SRPT
Executed On: Mar 26, 2025 at 12:00 PM EDT -
Discussing the recent death of a patient who was treated with Elevidys the effect on future prescribing and uptake
Ticker: SRPT
Executed On: Mar 24, 2025 at 06:00 PM EDT -
Reviewing the recent Duchenne Muscular Dystrophy Data from Wave Life Sciences on their exon 53 skipper, WVE-N531
Tickers: WVE, SRPT, RNA, NS Pharma
Executed On: Sep 26, 2024 at 11:00 AM EDT -
Reviewing Avidity Bioscience's Phase 1/2 data from their Explore 44 Trial of AOC 1044 for Duchenne Muscular Dystrophy treatment
Tickers: RNA, SRPT
Executed On: Aug 15, 2024 at 04:00 PM EDT -
Exploring Sarepta Therapeutics' Elevidys Gene Therapy for Duchenne Muscular Dystrophy ahead of June 21 PDUFA
Ticker: SRPT
Executed On: May 23, 2024 at 01:00 PM EDT -
Discussing Sarepta Therapeutics’ gene therapy, ELEVIDYS (delandistrogene moxeparvovec-rokl) and the recently announced results from the Phase 3 EMBARK study.
Ticker: SRPT
Executed On: Nov 03, 2023 at 02:00 PM EDT -
Discussing the potential of Sarepta Therapeutics’ investigational gene therapy, SRP-9001 (delandistrogene moxeparvovec) for the treatment of DMD with a pediatric cardiologist.
Ticker: SRPT
Executed On: Apr 11, 2023 at 10:00 AM EDT -
Discussing the potential of Sarepta Therapeutics’ investigational gene therapy, SRP-9001 (delandistrogene moxeparvovec) for the treatment of DMD with a pediatric neurologist.
Ticker: SRPT
Executed On: Apr 04, 2023 at 08:30 AM EDT -
Discussion of SRP-9001, expectations for possible AA and outlook for EMBARK Trial
Ticker: SRPT
Executed On: Oct 11, 2022 at 01:00 PM EDT -
Digesting the recent data from Sarepta's SRP-9001-102 study in treating Duchenne Muscular Dystrophy
Ticker: SRPT
Executed On: Jan 18, 2022 at 04:00 PM EST
Expired Projects (SRPT)
-
Discussing Sarepta’s Gene Therapy Pipeline in Treating Limb-Girdle Muscular Dystrophy
Ticker: SRPT
Execute By: Oct 29, 2021 -
Discussing the Potential of Summit's (SMMT) Ezutromid in Duchenne Muscular Dystrophy After Initiation of Phase 2 Enrollment
Tickers: SMMT, SRPT
Execute By: Jan 04, 2017 -
What Does Sarepta’s Exon 51 Approval Mean for its 9 Other Exon Skipping Product Candidates and Company Future?
Ticker: SRPT
Execute By: Nov 11, 2016
Upcoming & Overdue Catalysts (SRPT)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (SRPT)
-
Sarepta's (SRPT) Casimersen in Duchenne muscular dystrophy PDUFA date under priority review February 25, 2021
Ticker: SRPT
Occurred on: Feb 25, 2021 -
Sarepta's (SRPT) Golodirsen (SRP-4053) in Duchenne muscular dystrophy PDUFA date due August 19, 2019
Ticker: SRPT
Occurred on: Aug 19, 2019 -
Phase 1/2 data of Sarepta's (SRPT) MYO-101 in Duchenne muscular dystrophy - LGMD2E due February 27, 2019
Ticker: SRPT
Occurred on: Feb 27, 2018 -
Preliminary read out of open label Phase 3 study in DMD of eteplirsen
Tickers: SRPT, BMRN, PTCT
Occurred on: Dec 27, 2017 -
Phase 1/2 Study of Exon-Skipping Candidate SRP-4053 for Exon 53 Continues to Enroll Patient - Data Readout Expected H1 of 2017
Ticker: SRPT
Occurred on: Sep 06, 2017 -
Data from First Set of 24-week Biopsies Expected Q2 or Q3 for UK Enrolled DMD patients in the Ongoing PhaseOut DMD trial
Tickers: SMMT, BMRN, SRPT, PTCT
Occurred on: Jun 22, 2017 -
Sarepta (SRPT) Agrees to Sell Rare Pediatric Disease Priority Review Voucher for $125MM to Unnamed Party
Ticker: SRPT
Occurred on: Feb 21, 2017 -
Sarepta's (SRPT) Eteplirsen Approved by FDA for Duchenne Muscular Dystrophy After Long Approval Process
Tickers: SRPT, BMRN
Occurred on: Sep 19, 2016 -
Sarepta began recruiting patients for a Phase 3 trial to treat Duchenne muscular dystrophy with its lead product candidate, Eteplirsen
Ticker: SRPT
Occurred on: Aug 03, 2016 -
Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA
Ticker: SRPT
Occurred on: Jun 06, 2016 -
Eteplirsen PDUFA goal date extended by standard extension period of three months to May 26, 2016
Ticker: SRPT
Occurred on: May 25, 2016 -
Sarepta Therapeutics Announces FDA Will Not Complete the Review of the Eteplirsen New Drug Application By The PDUFA Date
Ticker: SRPT
Occurred on: May 25, 2016 -
FDA Advisory committee meeting for Sarepta Therapeutics' Eteplirsen
Tickers: SRPT, PTCT, BMRN
Occurred on: Apr 25, 2016 -
PDUFA action date for completion of FDA review of the eteplirsen NDA due February 26, 2016
Ticker: SRPT
Occurred on: Mar 14, 2016 -
FDA decision on Drisapersen approval in DMD: PDUFA 12/27/15
Tickers: BMRN, SRPT, PTCT
Occurred on: Jan 14, 2016 -
FDA Will Review BioMarin's (BMRN) New Drug Application for Duchenne Muscular Dystrophy Candidate Drisapersen on November 24, 2015
Tickers: BMRN, SRPT, PTCT
Occurred on: Nov 24, 2015
Strategic Initiatives (SRPT)
-
Sarepta Announces Long Term Plan to Consolidate Facilities within Massachusetts
Ticker: SRPT
Announcement Date: Mar 08, 2016
